| NILOTINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | polycythemia vera | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | endometrial cancer | Bcr/Abl fusion protein | 0.5 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Terminated | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | sarcoma | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | malignant pleural mesothelioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | adult T acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Suspended | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | small intestine cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| PONATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein inhibitor | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | stomach neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | extranodal nasal NK/T cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | uterine sarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | kidney cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | polycythemia vera | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | pancreatic adenocarcinoma | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | childhood acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | asthma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | myeloid leukemia | Bcr/Abl fusion protein | 4.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | myelodysplastic syndrome | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | multiple myeloma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gliosarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | Uterine Carcinosarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | mesothelioma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | tuberculosis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Uterine Carcinosarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary hypertension | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pulmonary venoocclusive disease | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | T-lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | gastric cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | graft versus host disease | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Mantle cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | fallopian tube cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | COVID-19 | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | myelodysplastic syndrome | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | nephrogenic fibrosing dermopathy | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | Alzheimer disease | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein inhibitor | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | malignant epithelial tumor of ovary | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | colorectal adenocarcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 4.0 | - | ATC |
| DASATINIB | Small molecule | neuroblastoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| RADOTINIB | Small molecule | Parkinson disease | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | soft tissue sarcoma | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lung cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 4.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | mixed phenotype acute leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | polycythemia vera | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | undifferentiated high grade pleomorphic sarcoma of bone | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | hepatosplenic T-cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myeloproliferative disorder | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | childhood T acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | colorectal carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | Dementia | Bcr/Abl fusion protein | 1.0 | Enrolling by invitation | ClinicalTrials |
| IMATINIB | Small molecule | thyroid cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | low grade glioma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | B-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | plexiform neurofibroma | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | B-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | kidney cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | mesothelioma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | stroke | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | gliosarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| NILOTINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic graft versus host disease | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | malignant glioma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | DailyMed |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | endometrial cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | adult T-cell leukemia/lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | metastatic prostate cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | pigmented villonodular synovitis | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | small intestine lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | thyroid cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | graft versus host disease | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | metastatic malignant neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chondrosarcoma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | Sezary's disease | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | biliary tract cancer | Bcr/Abl fusion protein inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myeloproliferative disorder | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | gliosarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastric cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | graft versus host disease | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | idiopathic pulmonary fibrosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | anaplastic large cell lymphoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 0.5 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | asthma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | brain disease | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | Plasmodium falciparum malaria | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | hematopoietic and lymphoid cell neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | mesothelioma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | pancreatic adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | primary myelofibrosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | Thymoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Spinal cord injury | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | mesothelioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 4.0 | - | ATC |
| IMATINIB MESYLATE | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | scleroderma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | neoplasm | Bcr/Abl fusion protein inhibitor | 4.0 | - | ATC |
| DASATINIB | Small molecule | childhood cancer | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | childhood B acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | scleroderma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Hodgkins lymphoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Withdrawn | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | FDA |
| DASATINIB | Small molecule | multiple myeloma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | brain neoplasm | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | myeloid leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | chordoma | Bcr/Abl fusion protein | 1.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | MALT lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | kidney disease | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| RADOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 4.0 | - | ATC |
| DASATINIB | Small molecule | hairy cell leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | DailyMed |
| IMATINIB MESYLATE | Small molecule | uterine sarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | anaplastic large cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Plasmodium falciparum malaria | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | pigmented villonodular synovitis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | papillary thyroid carcinoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | systemic mastocytosis | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| DASATINIB | Small molecule | diffuse large B-cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| DASATINIB | Small molecule | Splenic Marginal Zone Lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | nephrogenic fibrosing dermopathy | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | T-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| VODOBATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| NILOTINIB | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Hypereosinophilic syndrome | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| VODOBATINIB | Small molecule | Dementia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | T-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| PONATINIB | Small molecule | cancer | Bcr/Abl fusion protein inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | sickle cell anemia | Bcr/Abl fusion protein | 0.5 | Recruiting | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | localised scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | neuroblastoma | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | male breast carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | rheumatoid arthritis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chordoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acral lentiginous melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | medullary thyroid gland carcinoma | Bcr/Abl fusion protein inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | skin neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | rectum cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | childhood T acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | T-cell large granular lymphocyte leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | skin neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | uterine cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | head and neck malignant neoplasia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic lymphocytic leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | fibrosarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | undifferentiated high grade pleomorphic sarcoma of bone | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Suspended | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | lymphoid neoplasm | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | sarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | mesothelioma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | idiopathic pulmonary fibrosis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | chronic lymphocytic leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | non-Hodgkins lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | rectum cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | core binding factor acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | lymphangioleiomyomatosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | malignant peripheral nerve sheath tumor | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | wet macular degeneration | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | Hypereosinophilic syndrome | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | nephrogenic fibrosing dermopathy | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acral lentiginous melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 0.5 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | Parkinson disease | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | head and neck malignant neoplasia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | Digestive System Carcinoma | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | scleroderma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | Eosinophilia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | pancreatic adenocarcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastric cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | Parkinson disease | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | multiple myeloma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | asthma | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | multiple sclerosis | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | gastric adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | lung cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | neurofibromatosis type 1 | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | breast carcinoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | head and neck malignant neoplasia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | lymphoid neoplasm | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| VODOBATINIB | Small molecule | Parkinson disease | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | COVID-19 | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | mycosis fungoides | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | metastatic colorectal cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | chronic lymphocytic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | lung adenocarcinoma | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | multiple sclerosis | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | primary myelofibrosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | lymphoid leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | dermatofibrosarcoma protuberans | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary venoocclusive disease | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | non-Hodgkins lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | Burkitts lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | synovial sarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | localised scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | loiasis | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | colonic neoplasm | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | follicular lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | mesothelioma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gliosarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | colorectal carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | Parkinson disease | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | cirrhosis of liver | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | dermatofibrosarcoma protuberans | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | plexiform neurofibroma | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | squamous cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| ASCIMINIB HYDROCHLORIDE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | FDA |
| DASATINIB | Small molecule | multiple myeloma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | fallopian tube cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic lymphocytic leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | childhood B acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | male breast carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | desmoplastic small round cell tumor | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| VODOBATINIB | Small molecule | Parkinson disease | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | asthma | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | prostate cancer | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastric adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | type 1 diabetes mellitus | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | low grade glioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | type 1 diabetes mellitus | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 4.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | cutaneous melanoma | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | Alzheimer disease | Bcr/Abl fusion protein | 3.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | sickle cell anemia | Bcr/Abl fusion protein | 0.5 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | unspecified peripheral T-cell lymphoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | urinary bladder cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | cancer | Bcr/Abl fusion protein inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary hypertension | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | clear cell renal carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | melanoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Hypereosinophilic syndrome | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | adult B acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | childhood acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | COVID-19 | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | cervical cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | glioma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Merkel cell skin cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | fibromatosis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | major salivary gland cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | peritoneum cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 0.5 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | hepatocellular carcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | DailyMed |
| PONATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| PONATINIB | Small molecule | leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | thyroid neoplasm | Bcr/Abl fusion protein inhibitor | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | malignant epithelial tumor of ovary | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | angioimmunoblastic T-cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| IMATINIB | Small molecule | sarcoma | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | Vestibular schwannoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | gastric cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | systemic mastocytosis | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 4.0 | Unknown status | ClinicalTrials |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | - | DailyMed |
| IMATINIB | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | mixed phenotype acute leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | lymphoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| ASCIMINIB | Small molecule | neoplasm | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | sarcoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | synovial sarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Waldenstrom macroglobulinemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lymphoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | breast carcinoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | aging | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Eosinophilia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | kidney cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | metastatic prostate cancer | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | sarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Waldenstrom macroglobulinemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | childhood acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lung injury | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | salivary gland adenoid cystic carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | prostate cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | metastatic malignant neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | hepatocellular carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | fallopian tube cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 0.5 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lymphoid leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chordoma | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | lymphoid leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | cholangiocarcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | Huntington disease | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | non-Hodgkins lymphoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | Hepatobiliary Neoplasm | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | endometrial cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | diffuse intrinsic pontine glioma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | T-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| NILOTINIB | Small molecule | cutaneous melanoma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | head and neck squamous cell carcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | prostate cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | graft versus host disease | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | non-Hodgkins lymphoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | non-Hodgkins lymphoma | Bcr/Abl fusion protein | 1.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | myeloid leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | primary peritoneal carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | T-cell acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | sarcoma | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| RADOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BOSUTINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 4.0 | - | ATC |
| IMATINIB | Small molecule | colorectal cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | lymphangioleiomyomatosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | giant cell tumor | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | systemic mastocytosis | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | peritoneum cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 0.5 | Active, not recruiting | ClinicalTrials |
| OLVEREMBATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | loiasis | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | myeloid leukemia | Bcr/Abl fusion protein | 4.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | Hodgkins lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic kidney disease | Bcr/Abl fusion protein | 2.0 | Enrolling by invitation | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 0.5 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | COVID-19 | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | HIV-1 infection | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| ASCIMINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Not yet recruiting | ClinicalTrials |
| IMATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | rhabdomyosarcoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | wet macular degeneration | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | neurofibromatosis type 1 | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | myelodysplastic syndrome | Bcr/Abl fusion protein inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | cutaneous melanoma | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| BOSUTINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | seasonal allergic rhinitis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Bcr/Abl fusion protein inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | peritoneum cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Not yet recruiting | ClinicalTrials |
| PONATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | acral lentiginous melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| PONATINIB HYDROCHLORIDE | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | diffuse intrinsic pontine glioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | colorectal carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | cutaneous melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | glioblastoma multiforme | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Terminated | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | small cell lung carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 4.0 | Unknown status | ClinicalTrials |
| BOSUTINIB | Small molecule | Autosomal dominant polycystic kidney disease | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | aging | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | peritoneum cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein inhibitor | 4.0 | - | ATC |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | T-lymphoblastic lymphoma | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| PONATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein inhibitor | 4.0 | - | DailyMed |
| IMATINIB MESYLATE | Small molecule | sarcoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | plexiform neurofibroma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | cancer | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| RADOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | non-small cell lung carcinoma | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | Pineoblastoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | rectum cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | pulmonary hypertension | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | pulmonary arterial hypertension | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Merkel cell skin cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | nephrogenic fibrosing dermopathy | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| NILOTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Withdrawn | ClinicalTrials |
| DASATINIB | Small molecule | prostate adenocarcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | lymphoid leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | small intestine cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 3.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | chronic graft versus host disease | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic lymphocytic leukemia | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 3.0 | Active, not recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | diffuse large B-cell lymphoma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | mesothelioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | melanoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | mucosal melanoma | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| BOSUTINIB | Small molecule | amyotrophic lateral sclerosis | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | COVID-19 | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | Central Nervous System Neoplasm | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | thyroid cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | uterine cancer | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | metastatic malignant neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | chondrosarcoma | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| ASCIMINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | idiopathic pulmonary fibrosis | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | Hepatobiliary Neoplasm | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | cerebellar ataxia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | mesothelioma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | systemic scleroderma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | metastatic melanoma | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | adult acute lymphoblastic leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 2.0 | Withdrawn | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | melanoma | Bcr/Abl fusion protein | 2.0 | Recruiting | ClinicalTrials |
| IMATINIB | Small molecule | Thymic Carcinoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| BOSUTINIB | Small molecule | thymus cancer | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 2.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | myelodysplastic syndrome | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | acute myeloid leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | brain disease | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | kidney cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | lung cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | Desmoid-type fibromatosis | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| NILOTINIB | Small molecule | graft versus host disease | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | malignant colon neoplasm | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Recruiting | ClinicalTrials |
| DASATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 4.0 | Unknown status | ClinicalTrials |
| DASATINIB | Small molecule | neoplasm | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Bcr/Abl fusion protein | 1.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | Alzheimer disease | Bcr/Abl fusion protein | 1.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | gastrointestinal stromal tumor | Bcr/Abl fusion protein | 4.0 | Active, not recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | primary peritoneal carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | nodal marginal zone B-cell lymphoma | Bcr/Abl fusion protein | 1.0 | Completed | ClinicalTrials |
| PONATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein inhibitor | 3.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | leukemia | Bcr/Abl fusion protein | 2.0 | Unknown status | ClinicalTrials |
| PONATINIB | Small molecule | small cell lung carcinoma | Bcr/Abl fusion protein inhibitor | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | malignant peripheral nerve sheath tumor | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| BOSUTINIB | Small molecule | breast cancer | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | chronic graft versus host disease | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | acute lymphoblastic leukemia | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| IMATINIB | Small molecule | chronic myelogenous leukemia | Bcr/Abl fusion protein | 1.0 | Recruiting | ClinicalTrials |
| IMATINIB MESYLATE | Small molecule | plexiform neurofibroma | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| DASATINIB | Small molecule | pancreatic carcinoma | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |
| DASATINIB | Small molecule | breast neoplasm | Bcr/Abl fusion protein | 2.0 | Terminated | ClinicalTrials |
| IMATINIB | Small molecule | ovarian cancer | Bcr/Abl fusion protein | 2.0 | Completed | ClinicalTrials |